Distributors participating in the event include: OncoMedical (Switzerland and Liechtenstein), Science International Corp (Hong Kong and Macao), Konica Minolta (Japan), Celeritas Trading & Consulting (Mexico) and Colvin & Cia (Chile).

"In addition to expanding the product and clinical expertise of our partners, this event allows for a collaborative exchange of MedTech knowledge and experience from markets around the world," said Catarina Löwenadler, Dignitana CEO.  "With a superior product and a common goal of serving more patients, we can deepen our relationships and continue to expand our strategic initiatives into key markets."

The event allowed participants to focus on specific functions and knowledge needed for successful sales and implementation of DigniCap Delta in their region, including clinical training for patient-focused roles, technical service certification, as well as business and product insights to deepen their understanding scalp cooling therapy and  related business strategies. Some participants also shared their local outcomes that have demonstrated the superior efficacy of DigniCap Delta over other scalp cooling systems.

The FDA-cleared DigniCap Scalp Cooling System minimizes hair loss from chemotherapy for cancer patients with solid tumors such as breast, ovarian and prostate cancer.  It is available in its primary US market and in cancer centers around the globe. Recognized internationally as a standard of care and quality of life advancement for cancer patients, scalp cooling is a treatment recommendation in the clinical practice guidelines published by National Comprehensive Cancer Network (https://nccn.org/)® (NCCN), European Society for Medical Oncology (https://www.annalsofoncology.org/article/S0923-7534(20)43157-6/fulltext) (ESMO), and Cancer Australia (https://www.guidancebreastcancer.gov.au/sites/default/files/guidelines/GEBC_Recommendations%20and%20practice%20points_Pdf_Sept%202020.pdf).